Results 191 to 200 of about 146,730 (293)

Hyper-response to cardiac resynchronization with permanent His bundle pacing: Is parahisian pacing sufficient?

HeartRhythm Case Reports, 2015
Olujimi A. Ajijola, MD, PhD, Jorge Romero, MD, Gabriel Vorobiof, MD, William M. Suh, MD, Kalyanam Shivkumar, MD, PhD, FHRS, Roderick Tung, MD, FHRS   +5 more
doaj   +1 more source

Optogenetic quantification of cardiac excitability and electrical coupling in intact hearts to explain cardiac arrhythmia initiation. [PDF]

Sci Adv
Langen JS, Boyle PM, Malan D, Sasse P.
europepmc   +1 more source

Cardiac arrhythmias during laparoscopy. [PDF]

, 1972
J.E. Utting
openalex   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Arrhythmogenic right ventricular cardiomyopathy: Electroarchitecture of the substrate

HeartRhythm Case Reports, 2016
Atsuyuki Watanabe, MD, Atsuko Seki, MD, Michael C. Fishbein, MD, Kalyanam Shivkumar, MD, PhD, FHRS, Marmar Vaseghi, MD, MS, FHRS   +4 more
doaj   +1 more source

Cardiac arrhythmia in COVID-19 patients. [PDF]

Ann Noninvasive Electrocardiol
Yu L, Liu Y, Feng Y.
europepmc   +1 more source

Studies on the effect of physostigmine on experimental cardiac arrhythmias in dogs [PDF]

, 1972
Prasun Das, S. K. Bhattacharya
openalex   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Increased risk of cardiac arrhythmia in Hailey-Hailey disease patients. [PDF]

PLoS One
Jebril W, Curman P, Andersson DC, Larsson H, Bachar-Wikstrom E, Cederlöf M, Wikstrom JD.   +6 more
europepmc   +1 more source

Effect of Propranolol on Cardiac Arrhythmias Induced by Adrenaline under Halothane Anesthesia

, 1966
K Iwatsuki, T Yusa, Isamu Yasuda, Yasuhiko Hashimoto, Kotaro Takahashi, Naofumi Iwatsuki   +5 more
openalex   +2 more sources